Akso Health Group (AHG) Q4 2023 Earnings Report

AHG reported a markedly downbeat Q4 2023, highlighting a sharp revenue contraction and negative profitability. Q4 revenue of 662,240 USD fell ~92.5% year-over-year, with gross profit of 71,555 USD and a gross margin of 10.8%. The company operates with a heavy cost base, posting operating loss of 7.02 million USD and net loss of 7.41 million USD (EPS -0.99). Despite the loss, AHG’s balance sheet shows resilient liquidity, including cash and cash equivalents of 7.92 million USD and a current ratio of ~1.78, underscored by sizable net receivables and inventory. However, aggressive operating expenses (G&A approximately 7.09 million USD in the quarter) driven together with negative operating cash flow (CFO of -959,612 USD) contributed to substantial cash burn on an quarterly basis. FX movements contributed positively to cash by 1.33 million USD, while working capital dynamics saw sizable outflows (change in working capital -536,458 USD) and a negative free cash flow of -959,612 USD. The quarterly performance underscores ongoing profitability challenges and a fragile cash flow profile, necessitating sharper revenue generation and cost control to re-establish earnings momentum. No formal earnings-call transcript was provided in the supplied data, limiting quote-based management color. Investors should monitor topline stabilization, unit economics improvement, and a clear path to EBITDA profitability. In the near term, the key questions are whether AHG can scale revenue meaningfully while controlling overhead and optimizing working capital to turn cash flow positive.